Abstract
Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.
Original language | English |
---|---|
Article number | BSR20180201 |
Journal | Bioscience Reports |
Volume | 39 |
Issue number | 1 |
DOIs | |
State | Published - Jan 11 2019 |
Bibliographical note
Funding Information:The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health [grant numbers R01HL139748, R01HL133723] and the National Natural Science Foundation of China [grant numbers 81320108003, 31371498 (to Y.W.)]; Employees of Ionis Pharmaceuticals, Inc. [to A.E.M. and R.M.C.]; M.J.G. was an employee of Ionis Pharmaceuticals, Inc. The content in this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019 The Author(s).
ASJC Scopus subject areas
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology